HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.

The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.

Advanced prostate cancer is difficult to treat and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment, said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinais Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow not stop or shrink -- tumor growth.

The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time, said Agus. Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... January 23, 2015 AngelWeddingDress, the premier ... 2015 maternity wedding dresses. View website of ... looking for maternity wedding dresses online for a bridal ... with high quality for them. Its maternity wedding dresses ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ... directors of Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... breached its fiduciary duties to shareholders. On ... investing website reporting that Advaxis had misrepresented the clinical ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Cached News: